Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

被引：1

作者：

Lavie, David ^{[1
]}

Timmerman, John ^{[2
]}

Garcia-Sanz, Ramon ^{[3
]}

Kim, Won Seog ^{[4
]}

Kim, Tae Min ^{[5
]}

Avigdor, Abraham ^{[6
]}

Dierickx, Daan ^{[7
]}

Jagadeesh, Deepa ^{[8
]}

Molin, Daniel L. ^{[9
]}

Ozcan, Muhit ^{[10
]}

Sevindik, Omur Gokmen ^{[11
]}

Saeed, Hayder ^{[12
]}

Sidi, Yulia ^{[13
]}

Pillai, Pallavi ^{[13
]}

Marinello, Patricia ^{[13
]}

Herrera, Alex F. ^{[14
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[9] Uppsala Univ, Uppsala, Sweden

[10] Ankara Univ, Sch Med, Hematol Dept, Ankara, Turkiye

[11] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Merck & Co Inc, Rahway, NJ 07065 USA

[14] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Liu, Yang
Wang, Chunmeng
Li, Xiang
Dong, Liang
Yang, Qingming
Chen, Meixia
Shi, Fengxia
Brock, Malcolm
Liu, Miao
Mei, Qian
Liu, Jiejie
Nie, Jing
Han, Weidong
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)
[22] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song
Quanli Gao
Huilai Zhang
Lei Fan
Jianfeng Zhou
Dehui Zou
Wei Li
Haiyan Yang
Ting Liu
Quanshun Wang
Fangfang Lv
Haiyi Guo
Liudi Yang
Rebecca Elstrom
Jane Huang
William Novotny
Vivian Wei
Jun Zhu
Leukemia, 2020, 34 : 533 - 542
[23] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Elstrom, Rebecca
Huang, Jane
Novotny, William
Wei, Vivian
Zhu, Jun
LEUKEMIA, 2020, 34 (02) : 533 - 542
[24] KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
Kuruvilla, John
Ramchandren, Radhakrishnan
Santoro, Armando
Paszkiewicz-Kozik, Ewa
Gasiorowski, Robin
Johnson, Nathalie
Melnichenko, Vladimir
Fogliatto, Laura Maria
Goncalves, Iara
de Oliveira, Jose
Buccheri, Valeria
Perini, Guilherme Fleury
Goldschmidt, Neta
Alekseev, Sergey
Kryachok, Iryna
Sekiguchi, Naohiro
Zhu, Ying
Nahar, Akash
Marinello, Patricia
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Merryman, Reid W.
Redd, Robert A.
Nishihori, Taiga
Chavez, Julio
Nieto, Yago
Darrah, Justin M.
Rao, Uttam
Byrne, Michael T.
Bond, David A.
Maddocks, Kami J.
Spinner, Michael A.
Advani, Ranjana H.
Ballard, Hatcher J.
Svoboda, Jakub
Singh, Anurag K.
McGuirk, Joseph P.
Modi, Dipenkumar
Ramchandren, Radhakrishnan
Romancik, Jason
Cohen, Jonathon B.
Frigault, Matthew J.
Chen, Yi-Bin
Serritella, Anthony, V
Kline, Justine
Ansell, Stephen
Nathan, Sunita
Rahimian, Maryam
Joyce, Robin M.
Shah, Mansi
David, Kevin A.
Park, Steven
Beaven, Anne W.
Habib, Alma
Bachanova, Veronika
Nakhoda, Shazia
Khan, Nadia
Lynch, Ryan C.
Smith, Stephen D.
Ho, Vincent T.
LaCasce, Ann
Armand, Philippe
Herrera, Alex F.
BLOOD ADVANCES, 2021, 5 (06) : 1648 - 1659
[26] Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Nie, Jing
Wang, Chunmeng
Liu, Yang
Yang, Qingming
Mei, Qian
Dong, Liang
Li, Xiang
Liu, Jiejie
Ku, Wenjing
Zhang, Yan
Chen, Meixia
An, Xiaojing
Shi, Lu
Brock, Malcolm, V
Bai, Jie
Han, Weidong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1479 - +
[27] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Huang, Xiaojun
Qiu, Lugui
Jin, Jie
Zhou, Daobin
Chen, Xiequn
Hou, Ming
Hu, Jianda
Hu, Yu
Ke, Xiaoyan
Li, Junmin
Liang, Yingmin
Liu, Ting
Lv, Yue
Ren, Hanyun
Sun, Aining
Wang, Jianmin
Zhao, Chunting
Salman, Mariya
Sun, Steven
Howes, Angela
Wang, Jingzhao
Wu, Peng
Li, Jianyong
CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055
[28] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
Johnston, Patrick B.
Pinter-Brown, Lauren C.
Rogerio, Jaqueline Willemann
Warsi, Ghulam
Chau, Quincy
Ramchandren, Rod
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[29] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
Johnston, P. B.
Lewis, L. T.
Rogerio, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[30] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study (vol 22, pg 512, 2021)
Kuruvilla, J.
Ramchandren, R.
Santoro, A.
LANCET ONCOLOGY, 2021, 22 (05): : E184 - E184

← 1 2 3 4 5 →